IL299447A - Methods for administering anti-fibrotic therapy - Google Patents

Methods for administering anti-fibrotic therapy

Info

Publication number
IL299447A
IL299447A IL299447A IL29944722A IL299447A IL 299447 A IL299447 A IL 299447A IL 299447 A IL299447 A IL 299447A IL 29944722 A IL29944722 A IL 29944722A IL 299447 A IL299447 A IL 299447A
Authority
IL
Israel
Prior art keywords
compound
subject
dose
hours
administration
Prior art date
Application number
IL299447A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL299447A publication Critical patent/IL299447A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL299447A 2016-11-30 2017-11-29 Methods for administering anti-fibrotic therapy IL299447A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428163P 2016-11-30 2016-11-30
US201662432425P 2016-12-09 2016-12-09
PCT/US2017/063549 WO2018102323A1 (en) 2016-11-30 2017-11-29 Methods of administering anti-fibrotic therapy

Publications (1)

Publication Number Publication Date
IL299447A true IL299447A (en) 2023-02-01

Family

ID=60655162

Family Applications (3)

Application Number Title Priority Date Filing Date
IL299447A IL299447A (en) 2016-11-30 2017-11-29 Methods for administering anti-fibrotic therapy
IL266480A IL266480A (en) 2016-11-30 2019-05-06 Methods for administering antifibrotic therapy
IL289544A IL289544B2 (en) 2016-11-30 2022-01-02 Methods for administering anti-fibrotic therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL266480A IL266480A (en) 2016-11-30 2019-05-06 Methods for administering antifibrotic therapy
IL289544A IL289544B2 (en) 2016-11-30 2022-01-02 Methods for administering anti-fibrotic therapy

Country Status (11)

Country Link
US (3) US11207304B2 (enExample)
EP (2) EP3548025A1 (enExample)
JP (3) JP2020502054A (enExample)
KR (3) KR20230129628A (enExample)
CN (1) CN110087651A (enExample)
AU (3) AU2017366881A1 (enExample)
CA (2) CA3045455A1 (enExample)
IL (3) IL299447A (enExample)
MX (3) MX2019006143A (enExample)
TW (3) TWI891129B (enExample)
WO (1) WO2018102323A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI891129B (zh) 2016-11-30 2025-07-21 美商基因科技公司 投與抗纖維化療法之方法
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
TWI891129B (zh) 2016-11-30 2025-07-21 美商基因科技公司 投與抗纖維化療法之方法

Also Published As

Publication number Publication date
EP4470624A3 (en) 2025-01-08
AU2025238129A1 (en) 2025-10-23
AU2017366881A1 (en) 2019-05-30
EP4470624A2 (en) 2024-12-04
KR20220139450A (ko) 2022-10-14
WO2018102323A1 (en) 2018-06-07
TW201825093A (zh) 2018-07-16
JP2020502054A (ja) 2020-01-23
AU2023263548B2 (en) 2025-10-16
US20240197693A1 (en) 2024-06-20
TW202539656A (zh) 2025-10-16
IL289544A (en) 2022-03-01
AU2023263548A1 (en) 2023-11-30
TWI891129B (zh) 2025-07-21
IL289544B2 (en) 2023-06-01
TWI826361B (zh) 2023-12-21
JP2022058873A (ja) 2022-04-12
TW202412795A (zh) 2024-04-01
MX2020011766A (es) 2020-11-24
US11925624B2 (en) 2024-03-12
US11207304B2 (en) 2021-12-28
IL266480A (en) 2019-07-31
KR20190089862A (ko) 2019-07-31
CN110087651A (zh) 2019-08-02
JP7495951B2 (ja) 2024-06-05
US12310951B2 (en) 2025-05-27
KR20230129628A (ko) 2023-09-08
CA3247781A1 (en) 2025-07-09
US20190321344A1 (en) 2019-10-24
US20220184046A1 (en) 2022-06-16
KR102575344B1 (ko) 2023-09-06
CA3045455A1 (en) 2018-06-07
MX2023003924A (es) 2023-04-26
JP2023139157A (ja) 2023-10-03
MX2019006143A (es) 2019-10-17
EP3548025A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
US12310951B2 (en) Methods of administering anti-fibrotic therapy
EP3884947B1 (en) Increasing drug bioavailability in naltrexone therapy
US20130245122A1 (en) Diclofenac formulations and methods of use
US9801858B2 (en) Progress-supressing or improving agent for chronic kidney disease
US20220105087A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
HK40012787A (en) Methods of administering anti-fibrotic therapy